Arca
Skip to content
Tools
Tools

HSD11B1: 11-beta-hydroxysteroid dehydrogenase 1

Controls the reversible conversion of biologically active glucocorticoids such as cortisone to cortisol, and 11- dehydrocorticosterone to corticosterone in the presence of NADP(H).

  • Drugs that act on it: 5
  • Approved: 0
  • In phases 1 to 3: 5
  • Sponsors: 5

Who is on it, and how far along

Every drug ChEMBL records acting on HSD11B1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 5

Approved0

    Phase 30

      Phase 25

      • ABT-384
      • AZD-4017
      • BI-187004
      • BMS-823778 free base
      • MK-0736

      Phase 10

        Sponsors

        Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: 11-beta-hydroxysteroid dehydrogenase 1 inhibitor.
        ABT-384Phase 2AbbVieSmall moleculeInhibitor0
        AZD-4017Phase 2AstraZeneca PharmaceuticalsSmall moleculeInhibitor0
        BI-187004Phase 2Boehringer Ingelheim PharmaceuticalsSmall moleculeInhibitor0
        BMS-823778 free basePhase 2Bristol-Myers SquibbSmall moleculeInhibitor0
        MK-0736Phase 2Merck & Co. (MSD)Small moleculeInhibitor0

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Cortisone reductase deficiency0.57
        • Gastroesophageal reflux disease0.50
        • Peptic ulcer disease0.50
        • Digestive system disorder0.27
        • Knee pain0.24
        • Type 2 diabetes mellitus0.14
        • Exstrophy-epispadias complex0.12
        • Obesity disorder0.11
        • Hypertensive disorder0.10
        • Obesity due to melanocortin 4 receptor deficiency0.10
        • Neoplasm0.10

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4235, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P28845, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.